Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

Bengt Fellström; Alan G. Jardine; Roland E. Schmieder; Hallvard Holdaas; Kym M. Bannister; Jaap J. Beutler; Dong‐Wan Chae; Alejandro Chevaile; Stuart M. Cobbe; Carola Grönhagen‐Riska; José J. De Lima; R. Lins; Gert Mayer; Alan W. McMahon; Hans‐Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; S. Sonkodi; Gültekin Süleymanlar; Dimitrios Tsakiris; Vladimı́r Tesař; Vasil Todorov; Andrzej Więcek; Rudolf P. Wüthrich; Mattis Gottlow; Eva Johnsson; Faı̈ez Zannad

doi:10.1056/nejmoa0810177

Abstract

In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)

Keywords

RosuvastatinMedicineHazard ratioHemodialysisInternal medicineMyocardial infarctionPlaceboRosuvastatin CalciumClinical endpointConfidence intervalIncidence (geometry)Randomized controlled trialCardiology

Related Publications

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

James Shepherd , Gerard J. Blauw , Michael Murphy +17 more

Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-aged individuals, their efficacy and safety in elderly people is not fully established. Ou...

2002 The Lancet 3358 citations

High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>

Terje R. Pedersen

In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce...

2005 JAMA 1539 citations

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Peter Sever , Björn Dahlöf , Neil R Poulter +11 more

The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol loweri...

2003 The Lancet 3773 citations

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

John R. Guyton , David M. Herrington , Mary P. McGowan +3 more

The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or ...

2004 The American Journal of Cardiology 198 citations

PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

J Ames S Hepherd , S Tuart M. C Obbe , I An F Ord +6 more

Background. Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of p...

1995 3460 citations

Publication Info

Year: 2009
Type: article
Volume: 360
Issue: 14
Pages: 1395-1407
Citations: 1972
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1972

OpenAlex

Cite This

APA Style

                            
                                
                                    Bengt Fellström, 
                                
                                    Alan G. Jardine, 
                                
                                    Roland E. Schmieder
                                
                                et al.
                            
                            (2009). 
                            Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. 
                            New England Journal of Medicine
                            , 360
                            (14)
                            , 1395-1407.
                            https://doi.org/10.1056/nejmoa0810177
                        

Identifiers

DOI: 10.1056/nejmoa0810177